Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.
Diafiltration of a protein solution into a new buffer is a common final step in biopharmaceutical manufacturing. However, the excipient concentrations in the retentate are not always equal to their corresponding concentrations in the new buffer (diafiltration buffer). This phenomenon was observed repeatedly during diafiltration of different therapeutic monoclonal antibodies in which the concentrations of histidine and either sorbitol or sucrose (depending on which was chosen for the diafiltration buffer) in the retentate were lower than in the diafiltration buffer. Experimental studies and theoretical analyses of the ultrafiltration/diafiltration (UF/DF) step were carried out to determine the primary causes of the phenomenon and to develop a mathematical model capable of predicting retentate excipient concentrations. The analyses showed that retentate histidine concentration was low primarily because of repulsive charge interactions between positively-charged histidine molecules and positively-charged protein molecules, and that volume exclusion effects were secondary for like-charged molecules. The positively-charged protein molecules generate an electrical potential that cause an uneven distribution of charged histidine molecules. This interaction was used to construct a mathematical model based on the Poisson-Boltzmann equation. The model successfully predicted the final histidine concentration in the diafiltered product (retentate) from the UF/DF development and production runs, with good agreement across a wide range of protein and histidine concentrations for four therapeutic monoclonal antibodies. The concentrations of uncharged excipients (sorbitol or sucrose) were also successfully predicted using previously established models, with volume exclusion identified as the primary cause of differences in uncharged excipient concentrations in the retentate and diafiltration buffer.
Miao
Fudu
F
Purification Development, Pharmaceutical Development, Centocor R&D, Radnor, PA 19087, USA.
Velayudhan
Ajoy
A
DiBella
Elsie
E
Shervin
Jaclyn
J
Felo
Michael
M
Teeters
Mark
M
Alred
Patricia
P
D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000627:therapeutic use; D004358:Drug Therapy; D005079:Excipients / Q000032:analysis*; D005374:Filtration; D008962:Models, Theoretical; D013012:Sorbitol / Q000032:analysis; D013395:Sucrose / Q000032:analysis; D014462:Ultrafiltration
D000911:Antibodies, Monoclonal; D005079:Excipients; D013012:Sorbitol; D013395:Sucrose